What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Transaction summary

Transaction and post-transaction values based connected SEC Form 4 weighted mean acquisition terms of $5.68 connected June 22, 2026.

Key questions

• How does this transaction comparison to Lowrance's humanities activity?
  The 394,528-share merchantability is materially larger than Lowrance's erstwhile asles, reflecting a liquidity determination enabled by enactment exercises and a reduced remaining stock base.

• What is the value of the enactment workout and contiguous merchantability structure?
  Lowrance exercised 580,187 options and instantly sold 394,528 shares, with 185,659 shares withheld for taxes; each shares sold and withheld were related to the enactment workout and not to discretionary open-market income of antecedently held stock.

• What is Lowrance's ongoing equity vulnerability aft this event?
  He continues to clasp 536,032 shares of Common Stock straight aft the transaction.

• How did marketplace conditions subordinate to the timing of the sale?
  The transaction occurred arsenic the banal was priced astatine astir $5.68 per stock connected June 22, 2026, with Savara having delivered a 166.97% one-year instrumentality arsenic of that date, suggesting the merchantability monetized a play of beardown stock appreciation.

Company overview

* 1-year show calculated utilizing June 22, 2026 arsenic the notation date.

Company snapshot

• Savara develops inhaled GM-CSF therapy (molgramostim) for uncommon respiratory diseases, with the pb denotation successful Phase III trials for autoimmune pulmonary alveolar proteinosis.

• The steadfast operates a clinical-stage biopharmaceutical exemplary focused connected advancing proprietary cause candidates done regulatory milestones to thrust aboriginal gross via merchandise approvals oregon strategical partnerships.

• It targets patients suffering from uncommon lung disorders, with superior customers anticipated to beryllium specialty healthcare providers and hospitals treating these conditions.

Savara is simply a clinical-stage biotechnology institution specializing successful therapies for uncommon respiratory diseases. The institution leverages a focused pipeline strategy, with its pb plus successful late-stage development, to code important unmet aesculapian needs. Its competitory borderline lies successful targeting orphan indications with constricted attraction options, positioning the concern for imaginable worth inflection upon palmy objective outcomes.